Some days the tape hands you a clean story.

Some days the tape hands you a clean story. Today it handed you ten stories and buried the worst one inside a P/E of a hundred and twenty-two.

Let us run the slate.

Eaton opened up seven point three percent on the print, which is the biggest gap on today's board. The hook is that revenue fell fifteen point one percent year over year and yet EPS still grew three point two percent — that is a margin story, not a growth story, and the Street paid thirty-nine times earnings for it. I want to see exactly where those operating efficiencies are coming from before I believe this multiple is earned.

Cboe Global Markets gapped four point six percent, and the number that matters is EPS growth of fifty-three point five percent against revenue growth of only ten point six. That kind of operating leverage in an exchange business tells you fixed costs are finally working in their favor — but I want to know how much of that falls apart if volatility normalizes and volume comes off.

Anglogold Ashanti fell three point seven percent despite printing EPS growth of eighty-three point one percent year over year on a net margin above thirty-one percent — that is the most interesting negative gap on the board. The market sold a gold miner printing those numbers, which almost always means the forward guidance or the cost structure said something the headline did not.

Ares Management grew revenue thirty-eight and a half percent and the stock only moved three point two percent. At forty-four times earnings for an alt manager, the Street has already priced in the growth — the question is whether fee-earning AUM can sustain that trajectory as fundraising cycles get longer.

Now let us talk about AbbVie. EPS down thirteen and a half percent. Net margin at five point eight percent. P/E at a hundred and twenty-two point nine. Here is the knife: the Humira cliff is not a surprise but the replacement portfolio — Skyrizi, Rinvoq — is still absorbing the revenue gap while the company carries an enormous debt load from the Allergan acquisition, which means margin compression is structural, not cyclical, and that P/E is not a value, it is a bet that the new drugs grow fast enough before the balance sheet becomes a conversation. That name gets a full teardown.

Chevron fell thirty-three point nine percent on EPS year over year. Revenue was only down three point six percent — that spread tells you energy margins got crushed, not volumes, and with oil prices still uncertain the near-term earnings recovery is not obvious at thirty-five times.

Cameco printed EPS growth of a hundred and sixty-one point eight percent and traded down two point one percent. Uranium economics are working. The market does not fully trust the durability yet, and at eighty-two times earnings, that skepticism is rational.

Church and Dwight grew EPS thirty point one percent on two point two percent revenue growth and the stock barely moved. Quiet operating leverage in consumer staples — not exciting, but worth watching.

Dominion Energy grew revenue nineteen point four percent and EPS twenty-seven percent and the stock did essentially nothing. Utility with data center exposure — the Street has heard this pitch enough times that it needs proof in the capital expenditure line, not the press release.

Colgate-Palmolive, EPS down twenty-seven percent on four point three percent revenue growth. Volume is there. Margin is not. That is a cost structure problem and it does not resolve in one quarter.

Coming up in full teardowns — AbbVie, because a hundred and twenty-two times earnings on a transitional pharma balance sheet deserves every page of scrutiny, and Anglogold Ashanti, because when a miner prints those margins and still gets sold, the footnotes are doing work.

That is the menu. The numbers were always there — most people just do not look. See you at the next filing.